Ferring Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ferring Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#271 of 15,742 sponsors by registered trial count).
Ferring Pharmaceuticals: 83 sponsored US clinical trials, 4 recruiting.
Ferring Pharmaceuticals sponsors 83 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 68 completed. 45 of these trials are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cervical Ripening, with 4 trials.
Top-decile sponsor footprint
Ferring Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#271 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
68 of 79 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
83 total, page 2 of 2
Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee
NCT00988091
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
NCT00947882
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
NCT00950105
A Trial of Degarelix in Patients With Prostate Cancer
NCT00946920
A Study of Degarelix in Patients With Prostate Cancer
NCT00928434
Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
NCT00828711
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
NCT00833248
A Study With Pentasa in Patients With Active Crohn's Disease
NCT00862121
Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females
NCT00796289
Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
NCT00805935
MENOPUR® Versus FOLLISTIM®
NCT00802360
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
NCT00615836
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
NCT00477490
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
NCT00468286
A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding
NCT01280981
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
NCT00451958
Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC
NCT00423371
Efficacy and Safety of XP12B in Women With Menorrhagia
NCT00401193
Efficacy and Safety Study of XP12B in Women With Menorrhagia
NCT00386308
A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee
NCT00379236
Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor
NCT00308711
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
NCT00295750
Safety Study of XP12B in Women With Menorrhagia
NCT00113568
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
NCT00117286
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH
NCT00296465
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
NCT00116753
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
NCT00116779
Extension Study of Semapimod 60 mg IV x 3 Days
NCT00741910
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
NCT00740103
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
NCT00739986
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
NCT00117312
CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
NCT00038766
Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
NCT00117949
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 28 |
| Phase 3 | 40 |
| Phase 4 | 5 |
What is open in the Ferring Pharmaceuticals pipeline
4 recruiting of 83 indexed (5% open); 68 completed (82%).
Phase mix: 45 late (III/IV) vs 33 early (I/II) (balanced across stages).
Top condition: Cervical Ripening (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ferring Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 83 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Ferring Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 83 trials (± recruiting share)
- National Jewish Health · 83 trials · 8% recruiting
- New York University · 83 trials · 30% recruiting
- Teva Pharmaceuticals USA · 83 trials · 0% recruiting
- Seagen · 84 trials · 0% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Amphastar Pharmaceuticals · 5% recruiting · 21 trials
- Cook County Health · 5% recruiting · 21 trials
- David Grant U.S. Air Force Medical Center · 5% recruiting · 21 trials
- Duquesne University · 5% recruiting · 21 trials
Related
What to do with this Ferring Pharmaceuticals page
83 registered trials is a research-attention snapshot, not an endorsement of Ferring Pharmaceuticals or any single study.
- 4 of Ferring Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cervical Ripening is the condition Ferring Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cervical Ripening trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ferring Pharmaceuticals pipeline card: 83 registered trials from official public datasets.Report a data error.